UCB completed the acquisition of Zogenix for $1.9bn.

UCB, a global biopharmaceutical company, completed the acquisition of Zogenix, a pharmaceutical company, for $1.9bn. "The proposed acquisition of Zogenix reinforces UCB's sustainable patient value strategy and continued commitment to addressing unmet needs of people living with epilepsy with an increasing focus on those living with specific or rare forms of epilepsy, where few options exist. Complementing UCB's existing therapeutic offerings, the Zogenix acquisition provides UCB with an approved medicine for a life-threatening, rare infant- and childhood-onset epilepsy marked by frequent and severe treatment-resistant seizures, that are particularly challenging to treat," Charl van Zyl, UCB Executive Vice President, Neurology & Head of Europe. On January 20, 2022, Shares of Zogenix soared more than 60% after UCB's bid.